The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mal'tsev A.V.

GUZ "Gorodskaia klinicheskaia bol'nitsa #12" DZ Moskvy

Deĭkin A.V.

FGBU "Institut biologii gena" RAN, Moskva

Ovchinnikov R.K.

FGBU "Institut fiziologicheski aktivnykh veshchestv" RAN, Chernogolovka, Moskovskaia obl.;
FGBU "Nauchno-issledovatel'skiĭ institut obshcheĭ patologii i patofiziologii" RAN, Moskva

Chicheva M.M.

Institute of Physiologically Active Substances, Russian Academy of Sciences, Chernogolovka, Moscow oblast, Russia

Kovrazhkina E.A.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet;
NII tserebrovaskuliarnoĭ patologii i insul'ta, Moskva

Razinskaia O.D.

Bronovitskiĭ E.V.

FGBU "Institut fiziologicheski aktivnykh veshchestv" RAN, Chernogolovka, Moskovskaia obl.

Budevich A.I.

Scientific and Practical Centre of the National Academy of Sciences of Belarus on Animal Husbandry, Zhodino, Minsk oblast, Belarus

Kirikovich Yu.K.

Scientific and Practical Centre of the National Academy of Sciences of Belarus on Animal Husbandry, Zhodino, Minsk oblast, Belarus

Bachurin S.O.

Ustiugov A.A.

Skvortsova V.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet;
NII tserebrovaskuliarnoĭ patologii i insul'ta, Moskva

Dimebon delays the onset of symptoms of FUS-proteinopathy in transgenic mice

Authors:

Mal'tsev A.V., Deĭkin A.V., Ovchinnikov R.K., Chicheva M.M., Kovrazhkina E.A., Razinskaia O.D., Bronovitskiĭ E.V., Budevich A.I., Kirikovich Yu.K., Bachurin S.O., Ustiugov A.A., Skvortsova V.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(4): 64‑67

DOI: 10.17116/jnevro20171174164-67

Read: 721 times

Download PDF (RU)
Contact the author
Table of contents

DIMEBON DELAYS THE ONSET OF SYMPTOMS OF FUS-PROTEINOPATHY IN TRANSGENIC MICE
DIMEBON DELAYS THE ONSET OF SYMPTOMS OF FUS-PROTEINOPATHY IN TRANSGENIC MICE

To cite this article:

Mal'tsev AV, Deĭkin AV, Ovchinnikov RK, et al. Dimebon delays the onset of symptoms of FUS-proteinopathy in transgenic mice. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(4):64‑67. (In Russ.)
https://doi.org/10.17116/jnevro20171174164-67

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Objective. To evaluate an effect of dimebon on the onset of symptomatic stage in FUS.1—513 transgenic mice — a new genetic model of neurodegeneration, and to study the dynamics of disease progression in the terminal stage. Material and methods. The study was carried out on males of line FUS1—513 with the contribution of genes from CD1 strains. Mice of the experimental group (n=28) received dimebon with water in the concentration of 70 mcg/ml starting from the 35th day of life. The control group (n=25) did not receive the drug. Age, body mass of animals at the start of symptomatic stage and duration of symptomatic stage were assessed. Results. Application of dimebon can delay the onset of the manifestation of clinical symptoms of the neurodegenerative process in the experimental group (127.6±4.6 days) compared to the control group (110.6±4.2 days). The body mass was similar in both groups. Conclusion. Dimebon leads to an increase in the duration of presymptomatic stage and delays the manifestation of clinical symptoms. The changes in the dynamics of the pathological process in the symptomatic stage are not detected.

Keywords:

amyotrophic lateral sclerosis
FUS
dimebon
transgenic mice

Authors:

Mal'tsev A.V.

GUZ "Gorodskaia klinicheskaia bol'nitsa #12" DZ Moskvy

Deĭkin A.V.

FGBU "Institut biologii gena" RAN, Moskva

Ovchinnikov R.K.

FGBU "Institut fiziologicheski aktivnykh veshchestv" RAN, Chernogolovka, Moskovskaia obl.;
FGBU "Nauchno-issledovatel'skiĭ institut obshcheĭ patologii i patofiziologii" RAN, Moskva

Chicheva M.M.

Institute of Physiologically Active Substances, Russian Academy of Sciences, Chernogolovka, Moscow oblast, Russia

Kovrazhkina E.A.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet;
NII tserebrovaskuliarnoĭ patologii i insul'ta, Moskva

Razinskaia O.D.

Bronovitskiĭ E.V.

FGBU "Institut fiziologicheski aktivnykh veshchestv" RAN, Chernogolovka, Moskovskaia obl.

Budevich A.I.

Scientific and Practical Centre of the National Academy of Sciences of Belarus on Animal Husbandry, Zhodino, Minsk oblast, Belarus

Kirikovich Yu.K.

Scientific and Practical Centre of the National Academy of Sciences of Belarus on Animal Husbandry, Zhodino, Minsk oblast, Belarus

Bachurin S.O.

Ustiugov A.A.

Skvortsova V.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet;
NII tserebrovaskuliarnoĭ patologii i insul'ta, Moskva

Close metadata

References:

  1. Al-Chalabi A, Visscher PM. Motor neuron disease: Common genetic variants and the heritability of ALS. Nat Rev Neurol. 2014;10:10:549-550. doi:10.1038/nrneurol.2014.166
  2. Lysogorskaia EV, Abramycheva NY, Zakharova MN, Stepanova MS, Moroz AA, Rossokhin AV, Illarioshkin SN. Genetic studies of Russian patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2016;17:1-2:135-141. doi:10.3109/21678421.2015.1107100
  3. Shelkovnikova TA, Kulikova AA, Tsvetkov PO, Peters O, Bachurin SO, Buchman VL, Ninkina NN. Proteinopathies, neurodegenerative disorders with protein aggregation-based pathology. Mol Biol. 2012;46:3:362-374. doi:10.1134/S0026893312020161
  4. Bachurin SO, Ninkina NN, Tarasova TV, Shelkovnikova TV, Kovrazhkina EA, Smirnov AP, Razinskaya O, Skvortsova VI. Modeling of lateral amyotrophic sclerosis: a non-genetic method. Zhurnal Nevrol Psikhiatrii im. S.S. Korsakova. 2013;113:9:86-89. PMID: 24218707.
  5. Shelkovnikova TA, Peters OM, Deykin AV, Connor-Robson N, Robinson H, Ustyugov AA, Bachurin SO, Ermolkevich TG, Goldman IL, Sadchikova ER, Kovrazhkina EA, Skvortsova VI, Ling S-C, Da Cruz S, Parone PA, Buchman VL, Ninkina NN. Fused in Sarcoma (FUS) Protein Lacking Nuclear Localization Signal (NLS) and Major RNA Binding Motifs Triggers Proteinopathy and Severe Motor Phenotype in Transgenic Mice. J Biol Chem. 2013;288:35:25266-25274. doi:10.1074/jbc.M113.492017
  6. Deĭkin AV, Kovrazhkina EA, Ovchinnikov RK, Bronovitskiĭ EV, Razinskaia OD, Smirnov AP, Ermolkevich TG, Eliakov AB, Popov AN, Fedorov EN, Lytkina OA, Kukharskiĭ MS, Tarasova TV, Shelkovnikova TA, Ustiugov AA, Ninkina NN, Gol'dman IL, Sadchikova ER, Bachurin SO, Skvortsova VI. A mice model of amyotrophic lateral sclerosis expressing mutant human FUS protein. Zhurnal Nevrol, Psikhiatrii im. S.S. Korsakova. 2014;114:8:62-69. PMID: 25345633
  7. Blackhall LJ. Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead. Muscle Nerve. 2012;45:3:311-318. doi:10.1002/mus.22305
  8. Katz JS, Barohn RJ, Dimachkie MM, Mitsumoto H. The Dilemma of the Clinical Trialist in Amyotrophic Lateral Sclerosis. Neurol Clin. 2015;33:4:937-947. doi:10.1016/j.ncl.2015.07.014
  9. Ittner LM, Halliday GM, Kril JJ, Götz J, Hodges JR, Kiernan MC. FTD and ALS-translating mouse studies into clinical trials. Nat Rev Neurol. 2015;11:6:360-366. doi:10.1038/nrneurol.2015.65
  10. Moujalled D, White AR. Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis. CNS Drugs. 2016;30:3:227-243. doi:10.1007/s40263-016-0317-8
  11. Bronovitsky EV, Deikin AV, Ermolkevich TG, Elyakov AB, Fedorov EN, Sadchikova ER, Goldman IL, Ovchinnikov RK, Roman AY, Khritankova IV, Kukharsky MS, Buchman VL, Bachurin SO, Ustyugov AA. Gamma-carboline inhibits neurodegenerative processes in a transgenic model of amyotrophic lateral sclerosis. Dokl Biochem Biophys. 2015;462:1:189-192. doi:10.1134/S1607672915030138
  12. Bachurin SO, Shelkovnikova TA, Ustyugov AA, Peters O, Khritankova I, Afanasieva MA, Tarasova TV, Alentov II, Buchman VL, Ninkina N, Dimebon N. Slows Progression of Proteinopathy in γ-Synuclein Transgenic Mice. Neurotox Res. 2012;22:1:33-42. doi:10.1007/s12640-011-9299-y
  13. Ustyugov A, Shevtsova E, Bachurin S. Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine). Mol Neurobiol. 2015;52:2:970-978. doi:10.1007/s12035-015-9249-4
  14. Ustyugov AA, Shelkovnikova TA, Kokhan VS, Khritankova IV, Peters O, Buchman VL, Bachurin SO, Ninkina NN. Dimebon reduces the levels of aggregated amyloidogenic protein forms in detergent-insoluble fractions in vivo. Bull Exp Biol Med. 2012;152:6:731-733. PMID: 22803176
  15. Yamashita M, Nonaka T, Arai T, Kametani F, Buchman VL, Ninkina N, Bachurin SO, Akiyama H, Goedert M, Hasegawa M. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett. 2009;583:14:2419-2424. doi:10.1016/j.febslet.2009.06.042
  16. Deykin AV, Ermolkevich TG, Gursky YG, Krasnov AN, Georgieva SG, Kuznetsov SL, Derevyanko VG, Novikova NI, Murashev AN, Gol'dman IL, Sadchikova ER. The state of health and the reproductive potential of transgenic mice secreting recombinant human lactoferrin in milk. Dokl Biochem Biophys. 2009;427:1:195-198. doi:10.1134/S1607672909040073
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.